‘The announcement of our second SPA via a phase III study demonstrates the breadth of the commercial opportunity with OncoVEX In addition to treating metastatic as the intention in our ongoing Phase 3 study in melanoma, according to multiple systemic reactions in phase II, OncoVEX also has considerable potential utility in treating discrete solid tumor masses across multiple indications, including those bad of serving radiation. As with tumors such as head and neck cancer where loco-regional progression of the primary cause of treatment failure in the treatment of discrete tumor masses is a major unmet need in a variety of settings malegra . It is our belief that as a result of this technology has the potential to in each arm. Study design – a broadly active new modality for significantly improving patient outcomes in a variety of hard – to-treat tumor types. ‘.
Phase I / II Trial Design and resultsin a phase I / II study, OncoVEX was administered by direct injection, at three dose levels, into tumor cells to lymph nodes in combination with standard first line chemo radiotherapy every three weeks for patients for four cycles all. Went for surgery. Of the 17 patients enrolled 16 had Stage IV N2 or N3 disease. 100 percent of has been shown that even without significant side effects in addition to those associated with chemoradiotherapy be tolerated. Efficacy, 93 percent of patients had a complete pathological response in the operation, with five patients. A complete reaction after 2 or 3 doses of virus No patient has been one loco-regional recurrence in the neck had. During a median follow – up of 30 months, and the disease-specific survival rate is currently 82 percent Coffin Coffin, Founder and Chief Technology Officer of BioVex said: – after ‘Loco – regional control is extremely important in head and neck cancer where loco regional development responsible for the majority of deaths, the two-year loco – regional. Failure rate front line treatment for about 30 percent free with a further 20 percent of patients progress to a remote location. Long-term loco-regional control of 100 percent with the high %age of patients, the disease remain in to combined to 40 months of treatment is very encouraging and inspires confidence, that OncoVEX will significantly reduce relapse rates with standard therapy alone in the pivotal study. Recently agreed with the FDA compared ‘.
‘Abdominal obesity is quicker than the general obesity increases. Of data from of data from the 2003-4 National Health and Nutrition Examination Survey, 61 percent of U.S. Women abdominal obesity based on waist measurement ‘.